Late carmustine lung fibrosis: Age at treatment may influence severity and survivalCitation formats

  • Authors:
  • B. R. O'Driscoll
  • S. Kalra
  • H. R. Gattamaneni
  • A. A. Woodcock

Standard

Late carmustine lung fibrosis: Age at treatment may influence severity and survival. / O'Driscoll, B. R.; Kalra, S.; Gattamaneni, H. R.; Woodcock, A. A.

In: Chest, Vol. 107, No. 5, 1995, p. 1355-1357.

Research output: Contribution to journalArticle

Harvard

O'Driscoll, BR, Kalra, S, Gattamaneni, HR & Woodcock, AA 1995, 'Late carmustine lung fibrosis: Age at treatment may influence severity and survival' Chest, vol. 107, no. 5, pp. 1355-1357.

APA

O'Driscoll, B. R., Kalra, S., Gattamaneni, H. R., & Woodcock, A. A. (1995). Late carmustine lung fibrosis: Age at treatment may influence severity and survival. Chest, 107(5), 1355-1357.

Vancouver

O'Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA. Late carmustine lung fibrosis: Age at treatment may influence severity and survival. Chest. 1995;107(5):1355-1357.

Author

O'Driscoll, B. R. ; Kalra, S. ; Gattamaneni, H. R. ; Woodcock, A. A. / Late carmustine lung fibrosis: Age at treatment may influence severity and survival. In: Chest. 1995 ; Vol. 107, No. 5. pp. 1355-1357.

Bibtex

@article{5a6de483aff14761a3b7833d805a089d,
title = "Late carmustine lung fibrosis: Age at treatment may influence severity and survival",
abstract = "Previously, we have reported in 1990 that 35{\%} of carmustine treated patients (6 of 17) who survived childhood brain tumors died of pulmonary fibrosis between 2 and 13 years after treatment. In addition, 8 patients studied in 1989 (13 to 17 years post treatment), had physiologic and biopsy or radiologic evidence of pulmonary fibrosis. We now report 3 more years of follow-up on these patients. Between 1989 and 1992, two more patients have died of pulmonary fibrosis, giving an overall mortality of 47{\%}. Of the eight patients who died of pulmonary fibrosis, the median age at treatment was 2.5 years, whereas the nine long-term survivors had a median age at treatment of 10 years. All five patients treated below the age of 5 years have died of lung fibrosis. Analysis by the standard survival curve method indicated that patients treated at an age less than 6 years were more likely to die than those treated at an age older than 7 years (p=0.03). Of the nine survivors, seven were observed over 3 more years. There was a gradual decline in mean forced vital capacity from 55{\%} predicted (range, 44 to 81) to 51{\%} predicted (range, 41 to 72) and total lung capacity fell from 65{\%} predicted (range, 51 to 89) to 57{\%} predicted (range, 47 to 77).",
keywords = "antineoplastic agents, BCNU, carmustine, interstitial lung disease, pulmonary fibrosis",
author = "O'Driscoll, {B. R.} and S. Kalra and Gattamaneni, {H. R.} and Woodcock, {A. A.}",
year = "1995",
language = "English",
volume = "107",
pages = "1355--1357",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

RIS

TY - JOUR

T1 - Late carmustine lung fibrosis: Age at treatment may influence severity and survival

AU - O'Driscoll, B. R.

AU - Kalra, S.

AU - Gattamaneni, H. R.

AU - Woodcock, A. A.

PY - 1995

Y1 - 1995

N2 - Previously, we have reported in 1990 that 35% of carmustine treated patients (6 of 17) who survived childhood brain tumors died of pulmonary fibrosis between 2 and 13 years after treatment. In addition, 8 patients studied in 1989 (13 to 17 years post treatment), had physiologic and biopsy or radiologic evidence of pulmonary fibrosis. We now report 3 more years of follow-up on these patients. Between 1989 and 1992, two more patients have died of pulmonary fibrosis, giving an overall mortality of 47%. Of the eight patients who died of pulmonary fibrosis, the median age at treatment was 2.5 years, whereas the nine long-term survivors had a median age at treatment of 10 years. All five patients treated below the age of 5 years have died of lung fibrosis. Analysis by the standard survival curve method indicated that patients treated at an age less than 6 years were more likely to die than those treated at an age older than 7 years (p=0.03). Of the nine survivors, seven were observed over 3 more years. There was a gradual decline in mean forced vital capacity from 55% predicted (range, 44 to 81) to 51% predicted (range, 41 to 72) and total lung capacity fell from 65% predicted (range, 51 to 89) to 57% predicted (range, 47 to 77).

AB - Previously, we have reported in 1990 that 35% of carmustine treated patients (6 of 17) who survived childhood brain tumors died of pulmonary fibrosis between 2 and 13 years after treatment. In addition, 8 patients studied in 1989 (13 to 17 years post treatment), had physiologic and biopsy or radiologic evidence of pulmonary fibrosis. We now report 3 more years of follow-up on these patients. Between 1989 and 1992, two more patients have died of pulmonary fibrosis, giving an overall mortality of 47%. Of the eight patients who died of pulmonary fibrosis, the median age at treatment was 2.5 years, whereas the nine long-term survivors had a median age at treatment of 10 years. All five patients treated below the age of 5 years have died of lung fibrosis. Analysis by the standard survival curve method indicated that patients treated at an age less than 6 years were more likely to die than those treated at an age older than 7 years (p=0.03). Of the nine survivors, seven were observed over 3 more years. There was a gradual decline in mean forced vital capacity from 55% predicted (range, 44 to 81) to 51% predicted (range, 41 to 72) and total lung capacity fell from 65% predicted (range, 51 to 89) to 57% predicted (range, 47 to 77).

KW - antineoplastic agents

KW - BCNU

KW - carmustine

KW - interstitial lung disease

KW - pulmonary fibrosis

M3 - Article

VL - 107

SP - 1355

EP - 1357

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -